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Highlights 
 A. baumannii can harbour many antibiotic resistance mechanisms   
 A. baumannii is responsible for outbreaks worldwide in both human and animals  
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 Animals may play a role as reservoir for A. baumannii 
 It is of importance to implement control measures in veterinary hospitals 
 Treatment should be based on in vitro antimicrobial susceptibility testing 
 
Abstract  
Acinetobacter spp. are aerobic, rod-shaped Gram-negative bacteria belonging to the 
Moraxellaceae family of the class Gammaproteobacteria and are considered ubiquitous 
organisms. Among them, Acinetobacter baumannii is the most clinically significant species 
with an extraordinary ability to accumulate antimicrobial resistance and survive in the hospital 
environment. Recent reports indicate that A. baumannii has also evolved into a veterinary 
nosocomial pathogen. Although Acinetobacter spp. can be identified to species level by the use 
of the matrix-assisted laser ionization time-of-flight mass spectrometry (MALDI-TOF MS) 
coupled with an updated database, molecular techniques are still necessary for genotyping and 
determination of clonal lineages. It seems that the majority of infections due to A. baumannii 
in veterinary medicine are nosocomial. Such isolates have been associated with several type of 
infections such as canine pyoderma, feline necrotizing fasciitis, urinary tract infections, equine 
thrombophlebitis and lower respiratory tract infections, foal sepsis, pneumonia in mink and 
cutaneous lesions in hybrid falcon. Given the potential multidrug resistance of A. baumannii, 
treatment of diseased animals is often supportive and should be based preferably on in vitro 
antimicrobial susceptibility testing. It should be noted that animal isolates show a high genetic 
diversity and are in general distinct in their sequence types and resistance patterns from those 
found in humans. However, it cannot be excluded that animals may occasionally play a role as 
reservoir for A. baumannii. In line, it is of importance to implement infection control measures 
in veterinary hospitals to avoid nosocomial outbreaks with multidrug-resistant A. baumannii. 
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1. Introduction 
Acinetobacter spp. are aerobic, rod-shaped Gram-negative bacteria belonging to the 
Moraxellaceae family of the class Gammaproteobacteria. Acinetobacter spp. occupy an 
important position in nature because of its ubiquitous presence in diverse environments such as 
soils, fresh water, oceans, and sediments [1,2]. Versatile metabolic characteristics allow species 
of this genus to catabolize a wide range of natural compounds, implying active participation in 
the nutrient cycle in the ecosystem. On the other hand, multidrug-resistant (MDR) 
Acinetobacter baumannii causing nosocomial infections with high mortality have been raising 
serious concerns in human medicine. It is very likely that A. baumannii will also evolve into a 
serious veterinary nosocomial pathogen similar to what happened in human hospitals as its 
association with infections in animals is increasingly reported. The lack of attention paid to A. 
baumannii in veterinary medicine is particularly worrying, as there are now reports indicating 
the presence of similarly or even identical successful clones in both humans and animals [3,4,5]. 
Despite this, data regarding A. baumannii of animal origin are still scarce [4]. Of importance, 
carbapenem-resistant A. baumannii rank priority one of the considered pathogens by the World 
Health Organization according to a recent publication [6]. 
This review aims to provide an overview of the A. baumannii epidemiology in animal species 
relevant to veterinary medicine. As numerous harmless non-baumannii Acinetobacter species 
occur in the environment and possibly in animals, identification of A. baumannii should be 
based on well validated methods like e.g. rpoB sequence analysis and matrix-assisted laser 
ionization time-of-flight mass spectrometry (MALDI-TOF MS) coupled with an updated 
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database [7,8]. In the present review we used “Acinetobacter spp.” if species identification was 
not defined or obtained with sufficiently powerful methodologies (Table 1). 
 
2. The Bacterium 
Nowadays, the genus Acinetobacter comprises more than 50 validly named species. Of note, 
many comprise only one strain and their ecology is not well known. They belong to the γ-
Proteobacteria and Pseudomonadales order and comprise a group of genetically related sugar-
non-fermenting, oxidase-negative Gram-negative and strictly aerobic cocco-bacilli [1,9,10]. 
The genus includes both non-pathogenic and pathogenic species [1,11]. Among them, A. 
baumannii is the most clinically significant Acinetobacter species that is implicated in human 
nosocomial infections. However, A. pittii and A. nosocomialis are also increasingly reported as 
causes of infections [10]. It should be noted that development of molecular methods in the last 
10 years also allowed a better identification of Acinetobacter species, and particularly of species 
of the Acinetobacter calcoaceticus-Acinetobacter baumannii (ACB) complex. For up-to-date 
information regarding the current taxonomy of the Acinetobacter genus please visit the website 
http://apps.szu.cz/anemec/Classification curated by prof. Alexandr Nemec. 
The clinically relevant species are mostly confined to the ACB complex: A. baumannii, A. 
calcoaceticus, A. pittii, A. nosocomialis, and the recently added species A. seifertii and A. 
dijkshoorniae of which A. baumannii is the most important one [12, 13]. Due to the association  
of MDR A. baumannii infections with high mortality, the bacterium has also been classified as 
an ESKAPE organism (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
A. baumannii, Pseudomonas aeruginosa, and Enterobacter species), a group of pathogens with 
a high rate of antimicrobial resistance that are responsible for an important part of human 
nosocomial infections [1,14]. Originally, three international A. baumannii clones (the so-called 
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International or European clones I, II, and III with preference of the use of International clones 
(IC)) have been reported from hospitals [15-18]. With the introduction of the multilocus 
sequence typing (MLST) [19], these clones I, II, and III have been shown to belong to specific 
sequence types (STs) which mainly cluster into three clonal complexes (CC)1, CC2 and CC3. 
There are two MLST approaches, the Pasteur [20] and Oxford [21] schemes and both of them 
can identify IC. 
Little is known about the natural occurrence of Acinetobacter species in animals or whether 
animals truely are a reservoir from which spread to humans occurs. It should be noted that some 
Acinetobacter spp. are commensal in animals as they may also represent the normal flora in 
humans, but these Acinetobacter spp. seem to be unrelated are in general distinct in their 
sequence types and resistance patterns from those found in humans. It is therefore important to 
use appropriate identification and genotyping methods in order to obtain comparable data. In 
this regard, the type of methodologies used in projects studying Acinetobacter sp. from animals 
is listed in Table 1 to determine whether A. baumannii has been correctly identified and whether 
results are reliable to evaluate the zoonotic aspect of A. baumannii. 
  
3. Antimicrobial Resistance and Pathogenesis 
 
A. baumannii has become one of the most problematic hospital-acquired human pathogens in 
the last two decades due to its ability to survive in the healthcare environment and to 
overexpress intrinsic β-lactamases, multidrug resistance efflux genes, as well as accumulate 
additional antimicrobial resistance traits [10,24]. Overexpression of chromosomally located β-
lactamases like the AmpC cephalosporinases (also known as ADCs [Acinetobacter-Derived 
Cephalosporinases) and the OXA-51-like oxacillinases have been associated with insertion 
sequence (IS) elements (e.g., ISAba1 and ISAba3) next to the genes [10,25,26]. Furthermore, 
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efflux pumps belonging to the resistance nodulation division (RND) family are particularly 
effective in generating resistance, as they form a tripartite complex together with the 
periplasmic proteins belonging to the membrane fusion protein (MFP) family and the outer 
membrane protein (OMP) channels, so that drugs are pumped out directly to the external 
medium [27,28]. The RND efflux complex in A. baumannii — AdeI (the MFP), AdeJ 
(transporter), together with AdeK (OMP) — was found to confer resistance to β-lactams, 
aminoglycosides, fluoroquinolones (FQs) and structurally unrelated compounds [29]. The first 
member of the RND family of exporters discovered in A. baumannii was the AdeABC system, 
which is known to pump out mostly aminoglycosides, tetracyclines, macrolides and FQs 
[10,30,31]. In addition to these resistance mechanisms, A. baumannii may acquire other 
resistance genes which specify for aminoglycoside-modifying enzymes, tetracycline efflux, 
sulfonamide resistance dihydropteroate synthase, and carbapenemases [10,32-35]. Among the 
carbapenemases which are specific β-lactamases able to hydrolyze almost all classes of β-
lactam antimicrobials [10], the OXA-type carbapenemases (OXA-23, OXA-24/40, OXA-58-, 
OXA-143-, OXA-235-group), as well as the KPC and NDM carbapenemases have already been 
acquired by human A. baumannii isolates seriously compromising the treatment outcome 
[2,3,10,36-38]. Of concern, carbapenem resistance is nowadays becoming common, accounting 
for the majority of A. baumannii strains in many hospitals over the world [10] with colistin 
(polymyxin E) remaining the last-resort antimicrobial [24]. The emergence of colistin-resistant 
A. baumannii is a serious public health concern as it limits the therapeutic options for patients 
[39]. Colistin resistance has been attributed to the loss of the LPS and to mutations into the 
PmrAB operon which lead to the addition of phosphoethanolamine to the lipid A region of LPS 
through the activation of the phosphoethanolamine transferase PmrC [40,41]. 
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Carbapenem resistance has been identified in different Acinetobacter species from animals 
including A. baumannii, the majority of them being associated with clinical infection cases 
(Table 2).  
Tracking antimicrobial resistance genes in A. baumannii as well as in other Acinetobacter 
species from animals revealed that they share common genes and genetic elements as those 
isolated from humans (Table 2). Among the isolates which acquired a carbapenemase gene, 
blaOXA-23 seems to be the most promiscuous since it has been identified in different animal hosts 
associated with transposons and plasmids, whereas blaNDM-1, blaIMP-1, blaOXA-58, blaOXA-72 were 
so far sporadically identified in different Acinetobacter species. In addition to acquired 
carbapenemases, these isolates may also contain resistance genes conferring resistance to other 
classes of antimicrobials like the aminoglycosides, tetracyclines, sulphonamides, phenicols, and 
macrolides (Table 2). Additionally, a few studies reported the presence of colistin resistance in 
Acinteobacter spp. from meat but the resistance mechanisms have not been characterized [42, 
43]. It should be noted that the number of studies characterizing the antimicrobial resistance 
mechanisms of Acinetobacter from animal origin is still very low compared to the large number 
of studies which reported resistance genes in isolates from humans [33,35,38,44,45].  
Bacterial factors known to play a role in the pathogenesis of A. baumannii are numerous 
and versatile likely contributing to its ability to survive and adapt in different environments and 
also cause a variety of infections in both humans and animals [33,46,47]. The virulence factors 
include porins, surface structures like capsular polysaccharides and lipopolysaccharide, 
phospholipases, iron acquisition systems, outer membranes vesicles, protein secretions systems, 
regulatory proteins, biofilm-associated proteins, as well as several different types of binding 
proteins and metabolitic and survival profiles like utilizing peptide nitrogen sources more 
efficiently and the thickness of biofilms formed, respectively [33,46,47]. Alterations in cell wall 
synthesis [the UDP-N-acetylmuramate-L-alanine ligase (MurC) protein] and upregulated 
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virulence-associated proteins (OmpA and YjjK) are proteins suggested to be fundamental for 
pathogenesis and virulence in the airways [48].  
The demonstrated ability of nosocomial isolates to grow as biofilm on both biotic and abiotic 
surfaces is believed to play a significant role in their persistence and antimicrobial resistance 
[31,49]. Consistently, although biofilm-infected wounds did not show marked differences in 
wound closure, the repaired skin demonstrated a disrupted epidermal barrier function [50]. This 
altered function was associated with two putative acyltransferases in A. baumannii designated 
LpxLAb and LpxMAb, which transfer one and two lauroyl (C12:0) acyl chains, respectively, 
during lipid A biosynthesis. LpxMAb-dependent acylation of lipid A is essential for A. 
baumannii desiccation survival, a key mechanism for survival in hospital settings [51]. Of note, 
iron starvation is not sensed as an overall biofilm-inducing stimulus by A. baumannii illustrating 
the impressive iron withholding capacity of this bacterium [52].  
 
4. Species identification and Genotyping 
Acinetobacter of the ACB complex can be identified to species level by the use of the MALDI-
TOF MS. Of note, MALDI-TOF MS and other systems are as good as their database are, i.e. 
they should include reference strains of all species, preferably multiple strains per species to 
cover the variation within species. As a consequence, the MALDI-TOF MS allows the 
identification of A. baumannii, A. pittii and A. nosocomialis with acceptable accuracy. It does 
not identify A. dijkshornii and A. seifertii still, but these species should also be identifyable by 
Maldi Tof once their mass spectra introduced into the database [53-55]. However, molecular 
techniques are still necessary to insure unambiguous species identification [56].  
The use of OXA-51 as a target gene has been advocated, but is not recommended since it may 
lead to false identification due to amplification of variants and presence of plasmid-located 
blaOXA-51-like genes in A. nosocomialis and in some non-baumanii Acinetobacter species like in 
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one clone of Acinetobacter genomic species close to 13TU [57,58]. Additionally, multiplex 
PCR showed atypical blaOXA-51-like amplification products in three clinical A. baumannii isolates 
Ab-508, Ab-511, and Ab-653 recovered from South Africa, South Korea, and Turkey, 
respectively [58]. Multiplex PCR targeting either gyrB alone or in combination with internal 
fragments of the 16S–23S rRNA intergenic region and the recA gene has been shown to be 
useful to differentiate A. baumannii, A. pittii, A. calcoaceticus and A. nosocomialis [59-61].  
Molecular methods have also been developed for genotyping and distinction between 
genetically diverse strains. These methods include whole-genome sequencing (WGS), PFGE, 
multi-locus variable-number tandem repeat analysis (MLVA), amplified fragment length 
polymorphism (AFLP) analysis, RNA spacer fingerprinting, rapid amplification of 
polymorphic DNA (RAPD), repetitive extragenic palindromic PCR (rep-PCR), single locus 
genotyping (e.g., rpoB, adeB, gyrB, recA and blaOXA-51-like genotyping), trilocus sequence 
typing (3LST) (ompA, csuE and blaOXA-51-like genes), and multi-locus sequence typing (MLST) 
[12,62-65]. Currently, both the Pasteur and Oxford MLST schemes remain the most widely 
used genotyping methods for the characterization of Acinetobacter spp., although the WGS will 
soon become essential, especially in outbreak situations [12]. So far, PFGE and PCR 
fingerprinting methods still represents methods with high resolving capacity to identify clones 
[63,66]. Other rapid molecular diagnostic methods like the single-locus-sequence-based typing 
of blaOXA-51-like genes have been used for rapid assignment of A. baumannii clinical isolates to 
IC lineages and multilocus broad PCR coupled with electrospray ionisation mass spectrometry 
(PCR/ESI-MS) has been developed as an alternative to MLST [2,67-71]. Furthermore, 
phenotypic features and antimicrobial spectra as well as plasmid typing and resistance island 
typing may be useful to some extent for epidemiological studies [65]. All these different 
epidemiological methods have been evaluated and discussed in a recent review according to the 
setting of application and the type of investigation like population structure studies, 
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epidemiological studies, as well as local- and large-scale investigation of A. baumannii 
dissemination and outbreaks [70].  
 
5. Zoonotical aspects 
 
The last two decades witnessed a surge in the incidence of infections due to several highly 
antimicrobial-resistant bacteria in hospitals worldwide. A. baumannii is one such organism that 
can develop from an occasional respiratory pathogen into a major nosocomial pathogen [1,10]. 
MDR A. baumannii belongs besides methicillin-resistant Staphylococcus aureus to the most 
frequently isolated bacteria during outbreaks in burn units, where they were also recovered from 
staff and environmental samples [72]. Outbreaks within a hospital may also be caused by 
several different A. baumannii strains including those resistant to carbapenem which may be 
introduced repeatedly or maintained in hospitals unnoticed. This emphasizes the need for 
molecular typing to trace back potential sources of the isolates and implement infection control 
interventions [73,74].  
It has been stated that animals can be a potential reservoir for A. baumannii and contribute to 
the dissemination of new emerging carbapenemases [75]. However, clear evidence 
demonstrating that the role of animals for the dissemination of Acinetobacter spp. to humans is 
lacking. Nevertheless, the situation may be different between the food producing animals and 
the companion animals, which are more in direct contact and vicinity with humans and more 
prone to transfer or acquire A. baumannii. Additionally, studies reporting Acinetobacter sp. in 
food-producing animals were made with healthy animals, while those of A. baumannii in 
companion animals include both carriage as well as clinical infection.  
In food-producing animals, it has been shown that Acinetobacter sp. isolates were not MDR 
and lacked significant antimicrobial resistance features such as resistance islands (RIs), class 1 
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integrons and IS Aba1 suggesting that MDR A. baumannii found in hospitals may not have 
directly evolved from from such animals and from food products made thereof [76]. Another 
study using pulsed-field gel electrophoresis (PFGE) typing also showed that A. baumannii 
isolated from food-producing animals were not MDR and belonged to a different pool from 
those of humans [22]. However, raw meat has been found to contain A. baumannii and may still 
play a role as a vehicle for the transmission of this bacterium from animals to humans [42, 43]. 
In Switzerland, A. baumannii was present in 25% of retailed meat samples with those derived 
from poultry being the most contaminated (48%) [42]. Resistance to piperacillin-tazobactam, 
ciprofloxacin, colistin, and tetracycline was only sporadically observed (about 2-5%). The 
absence of resistance to carbapenem does also not support the speculation of an animal reservoir 
of A. baumannii with mobile carbapenemase genes. In addition, the strains were genetically 
very diverse from each other and belonged to 29 different STs, forming 12 singletons and 6 
clonal complexes (CCs), of which three were new (CC277, CC360, and CC347). Of note, A. 
baumannii belonging to CC already detected in humans (i.e., CC32, CC33, CC79) were found 
in these meat samples, emphasizing that food cannot be excluded as a potential source for 
dissemination. In Portugal, different Acinetobacter spp. were detected in all the 50 meat 
products (chicken, turkey, pork, and beef) analysed with 166 isolates identified to belong to 
thirteen different Acinetobacter species [43]. The most common species was A. guillouiae 
(n=35) followed by A. johnsonii (n=25), and A. bereziniae (n=20). Thirty one of the 166 strains 
were identified as members of the A. baumannii group including A. baumannii (n = 7), A. pittii 
(n = 12), A. seifertii (n = 8) and A. nosocomialis (n = 4) [43]. Among the seven isolates identified 
as A. baumannii, one from turkey exhibited resistance to amikacin, tetracycline and colistin and 
one from chicken was resistant to meropenem [43]. In Lebanon, MLST analyses of 
Acinetobacter species from different environmental, food and animal origin revealed the 
presence of 36 STs, among which 24 were novel. The blaOXA-51 sequence-based gene typing 
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showed the presence of 34 variants, among which 21 were novel and all were isolated from 
animals. Finally, 30 isolates had new partial rpoB sequences indicating the high genetic 
diversity among Acinetobacter species and importance of accurate identification methods. 
Overall, 161 Acinetobacter species isolates were recovered, and among them, 42 were 
identified as A. baumannii by rpoB gene sequencing. The other identified species were A. pittii 
(n=61), A. bereziniae (n=10), A. calcoaceticus (n=4), A. johnsonii (n=1), A. lwoffii (n=1), A. 
schindleri (n=3), A. radioresistens (n=1), A. beijerinckii (n=1), A. junii (n=1), A. soli (n=1), A. 
gerneri (n=1), A. variabilis (n=4), as well as 30 possible novel Acinetobacter species. This wide 
variability and uniqueness of sequence types does not support the idea of animals as a reservoir 
of (nosocomial) A. baumannii either. Furthermore, A. baumannii was detected in 6.9% of the 
environmental water samples, 2.7% of the milk samples, 8.0% of the meat samples, 14.3% of 
the cheese samples, and 7.7% of the animal samples. All isolates showed a susceptible 
phenotype against most of the antimicrobials tested and lacked carbapenemase-encoding genes, 
except one carrying the blaOXA-143[75]. Importantly, a few studies reported the presence of 
acquired carbarpenemase genes in A. baumannii from food-producing animals like blaOXA-23 in 
a cow cattle and in a pig in Lebanon and blaNDM-1 in a pig in China [77,78] indicating that 
further attention has to be paid to this potential reservoir.  
Presence of A. baumannii in companion animals has been investigated in clinical settings and 
frequently in association with infections. The prevalence of A. baumannii carriage was 6.5% in 
dogs and cats (9 carriers [2 cats and 7 dogs] out of 138 animals) in a veterinary clinic on the 
island Réunion, which belongs to French oversees departments [79]. In this population, 
hospitalization in a veterinary clinic (> one day) and antimicrobial treatment administered 
within the 15 preceding days were significantly associated (OR= 10.8 and 4.4, respectively) 
with A. baumannii carriage [79]. Of importance, an increase in prevalence of MDR 
Acinetobacter sp. (52 A. baumannii, and 3 A. pittii, 1 unidentified) was observed over 9 years 
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(from 2000-2008) in hospitalized companion animals at the Justus-Liebig-University, Germany 
[23]. PFGE and AFLP typing revealed the presence of IC types I, II and III suggesting possible 
exchange of A. baumannii between humans and animals [23]. Similarly, nineteen clinical 
isolates of A. baumannii collected from dogs (n=12), horses (n=4) and cats (n=3) in Switzerland 
were analysed and also belonged to IC types I, II and III [3]. Recent studies revealed the 
presence of acquired carbapenemase in clinical A. baumannii isolates from companion animals 
suggesting that they may be related to those from humans (Table 2). In two cases of UTI in a 
cat from Portugal and a dog from Thailand, OXA-23-producing ST2 A. baumannii was 
identified. A. baumannii ST2 producing OXA-23 were also reported in these countries in 
humans indicating that such clones may be adapted to both humans and animals representing a 
zoonotic lineage and possible community-acquisition [39,81). Another study revealed a 
possible endemicity of OXA-23-producing ST25 A. baumannii from urinary tract infections in 
cats and dogs in France, but the epidemiology appeared to be independent of that of humans 
since ST25 A. baumannii from humans in this country mostly harbored OXA-58 [5,82].  
To date, the zoonotic role of food-producing animals as reservoir for MDR seems to be low, 
even if carbapenemase-producing Acinetbacter sp. including A. baumannii have been 
sporadically isolated from cattle and pigs. However, the presence of A. baumannii in meat 
indicates that food may contribute to the dissemination of this bacterium in the community. On 
the other hand, infections caused by A. baumannii in animals and in humans are more likely to 
be associated with MDR isolates which belong to the same genetic lineages, but whose 
epidemiological origin may differ [3, 23]. The emergence of carbapenemase-producing A. 
baumannii in animals and presence of possible zoonotic lineages emphasize the importance of 
avoiding selection and spread of MDR A. baumannii in animals and humans. 
6. Veterinary host spectrum 
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The most frequently hospitalized animals are the companion animals with dogs, cats and horses 
being most relevant globally. As a consequence, most data regarding A. baumannii infections 
concern these animal species (Table 1). In general, these infections were commonly hospital-
acquired and involved various body sites (with a slight preponderance of wound infections and 
abscesses). Furthermore, the majority of animals had underlying diseases and risk factors that 
could favour nosocomial infections [3]. Clinical and epidemiological evidence indicated that 
these bacterial pathogens were responsible for an increase in both morbidity and mortality with 
about 15 [3] to 50% [83] of systemic infections resulting in death [3-5,23,83]. As horizontal 
transmission of A. baumannii may occur from human patients to the personnel and other 
patients in human hospital settings [1,10,84], we emphasize that  A. baumannii behaves to some 
extent as such in veterinary hospitals affecting severely ill patients, or those with an underlying 
condition or with indwelling devices. 
6.1. Dog 
A total of 7% of cultures for bacteriologic culture and susceptibility testing from canine 
intensive care unit (ICU) patients in the USA were positive for Acinetobacter spp. [85]. These 
samples were routinely submitted at the discretion of the clinician attending the case with input 
from board-certified critical care specialists. However, it should be noted that dogs also carry 
Acinetobacter spp. in their oral flora as it has been reported previously [86]. This finding 
underlines that Acinetobacter species are widely distributed in different natural niches and, 
apart from A. baumannii which developed into a clinically relevant species, the precise ecology 
and epidemiology of Acinetobacter is not well known. It is therefore not surprising that animals, 
which are in close contact with their environment, also carry different Acinetobacter species. It 
is therefore important to use appropriate identification methods to clearly identify the 
Acinetobacter species in cases of surveillance studies. Among the Gram-negative bacteria from 
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cases of canine pyoderma in Grenada (West Indies), the most common species isolated was 
Klebsiella pneumoniae (7.8%), followed by Acinetobacter spp. (6.9%) [87]. In addition, 
Acinetobacter spp. have also been reported in dogs with chronic eczema without clinical signs 
of secondary infection some time ago [88]. 
In a Swiss university veterinary hospital clinic, A. baumannii was isolated from 17 dogs over a 
2½-year period, representing a proportional morbidity of 7.3 per 1,000 ICU admissions [83]. In 
seven dogs, A. baumannii induced systemic illness, whereas 10 dogs showed signs of local 
infection. In all animals with systemic infections, and in 2 with localized infections, A. 
baumannii contributed to the death of the animal or led to its euthanasia. The low median animal 
trauma triage score at presentation showed that most animals from which A. baumannii was 
later isolated were not in a critical condition or in a debilitated state. However, all the animals 
had at least one device (e.g., indwelling urinary catheters, chest tubes, or central venous lines) 
that could have served as a port of entry for A. baumannii. Following this report, cases of 
infections were continued to be recorded in the same animal hospital, with 12 dogs developing 
an A. baumannii infection [3]. The isolates belonged to two main clonal lineages (as determined 
by rep-PCR and MLST) which were related to sequence types of IC I and II also of importance 
in human medicine. Of concern is the emergence of OXA-23 carbapenemase production in 
genetically diverse A. baumannii from dogs with UTI in France and Thailand, and from vaginal 
and phlegmon samples from dogs in Germany (Table 2)[5,81,89-91]. The two isolates from 
Germany belonged to ST10 (IC8) with the blaOXA-23 located on Tn2008 (89), whereas the two 
French isolates belonged to ST25 with the blaOXA-23 also located on Tn2008B. The same isolates 
were also found in cats with UTI in both countries [5,90]. The isolate from Thailand belonged 
to ST2 and contained blaOXA-23 on Tn2006. This isolate was found to be related to an OXA-23-
producing ST2 A. baumannii from a cat with UTI in Portugal as determined by rep-PCR (80). 
These canine cases were predominantly characterized by UTI (Table 1). 
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6.2. Cat 
In a Swiss university hospital clinic, A. baumannii with undefined resistance profile was 
isolated from two domestic shorthair cats associated with intravenous catheters inserted during 
pre-isolation over a 2½-year period. Both cats recovered [83]. Additionaly, a necrotizing 
fasciitis with septic shock caused by A. baumannii exhibiting resistance to gentamicin, FQs and 
tetracycline has been reported in a 4-year-old, sterilized female, domestic shorthair cat in the 
same hospital [92]. In Portugal, a MDR A. baumannii isolate caused an UTI in a 3-year-old 
outdoor cat presenting with dysuria and hematuria, illustrating that resistant isolates affecting 
felines do not exclusively circulate in hospital environments [80]. Aseptic urine culture revealed 
bacteriuria due to a ST2 A. baumannii, which has been associated with IC II. The isolate 
produced the OXA-23 carbapenemase and also exhibited resistance to 
sulfamethoxazole/trimethoprim, tetracycline, and FQs. The blaOXA-23 gene was located on 
transposon Tn2006. Another case of UTI caused by A. baumannii in a cat was also reported in 
Switzerland, but the isolate did not carry blaOXA-23. In the same animal hospital, another cat 
developed an A. baumannii infection after liver biopsy. Both isolates were clonal as determined 
by rep-PCR and belonged to ST12 (IC II), suggesting a nosocomial source of infection. The 
two isolates exhibited resistance to sulfamethoxazole/trimethoprim, tetracycline, and FQs [3]. 
OXA-23 producing A. baumannii has also been reported in cats with UTI in Germany and in 
France [5,90]. The isolate from Germany belonged to ST1 (IC I) and carried the blaOXA-23 on a 
54-kb plasmid [90]. The five isolates from France belonged to ST25 with blaOXA-23 located on 
Tn2008B. They were obtained from different clinics and in one of them, dogs were also affected 
with the same clone indicating nosocomial and community dissemination of OXA-23-
producing A. baumannii among companion animals (5). The infected cats mainly were affected 
regarding UTI and skin/wounds (Table 2).  
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6.3. Horse 
Faecal samples from 20 hospitalized horses at a teaching hospital in Belgium identified 4 not 
yet formally defined Acinetobacter species [93]. In another study from Belgium, seven A. 
baumannii were obtained from catheter tips originating from seven different horses. The 
organism was also isolated in pure culture from a case of thrombophlebitis [94]. Several reports 
indicated that the occurrence of A. baumannii in horses has not always been associated with 
disease [3,94-97]. On the other hand, Acinetobacter spp. sepsis and systemic inflammatory 
response syndrome–associated severe thrombocytopenia resulting in coagulopathy has been 
reported in a 48-hour-old orphan Thoroughbred colt [98]. 
6.4. Cattle 
Of note, only one A. baumannii isolate was recovered from 159 faecal samples of dairy cattle 
in the High Plains Region of the USA [99]. It contained a chromosomal blaOXA-51-like variant, 
blaOXA-497, an intrinsic OXA-51 variant of A. baumannii that confirms species identification. In 
Lebanon, a clonal A. baumannii isolate from faecal samples from livestock (comprising pigs, 
fowl and cattle) was found to possess both blaOXA-23 and blaOXA-58 genes [77]. Samples from 
the same species also contained a VIM-2 carbapenemase-producing Pseudomonas aeruginosa. 
In addition, three new blaOXA-51-like genes (blaOXA-148, blaOXA-149 and blaOXA-150), which have 
not been found previously in human A. baumannii, were identified in strains from bovine faecal 
samples [76]. Nine out of 50 feacal samples from a French dairy herd revealed Acinetobacter 
variabilis (formerly 15 TU [98]) possessing the blaOXA-23 on a Tn2008 [100], and 2 of 45 nasal 
and rectal samples samples from cattle in Germany revealed Acinetobacter indicus-like isolates 
harbouring blaOXA-23 localized on an interrupted Tn2008 transposon [101], suggesting that these 
Acinetobacter species may play a role in the dissemination of blaOXA-23 to A. baumannii. One 
A. baumannii ST2 harbouring blaOXA-23 was isolated from the feces of cattle in Lebanon [77]. 
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6.5. Pig 
Like cattle, pigs may also harbour A. baumannii. Healthy pigs sampled at slaughterhouses in 
Scotland were found to contain genetically related strains as determined by PFGE and bla OXA-
51 -like sequencing [76]. Compared with A. baumannii clinical isolates ECI, ECII and ECIII, the 
pig isolates had different PFGE patterns and were grouped in three different clusters (A, B and 
C) with genetic similarity ranging between 82% and 90%. One A. baumannii strain isolated in 
China from the lung sample of a pig with pneumonia and sepsis was found to harbor the 
carbapenemase gene blaNDM-1 on a plasmid [78]. In Lebanon, a blaOXA-23-producing A. 
baumannii ST491 was recoved from the feces of a healthy pig [77]. 
6.6. Other animals 
A. baumannii has also been isolated from a variety of different animals with different clinical 
signs including rabbit, ferret, snake, rat and duck in Germany [89]. An outbreak of fatal 
pneumonia and acute mortality associated with A. baumannii has been described in a group of 
farmed mink in the Netherlands. Gross post-mortem examination revealed extensive 
haemorrhagic pneumonia in examined animals. On histology, all the lung samples showed a 
suppurative and haemorrhagic bronchopneumonia [102]. Another fatal case of severe 
fibrinous–hemorrhagic pneumonia in a mink was reported in Spain. The main lesions of an 
acute, severe fibrinous–hemorrhagic pneumonia were associated with proliferation of 
coccobacilli identified as A. baumannii and generalized acute–subacute congestion [103]. In 
about 60% of predominantly hybrid falcons admitted to the Abu Dhabi Falcon Hospital with 
identically localized, yellowish discolored cutaneous lesions in the thigh and lateral body wall 
region, A. baumannii was co-cultured with Mycobacterium avium complex [104]. Culture of a 
choanal swab from a captive grey parrot with progressive dyspnoea and nasal discharge in 
Luxemburg revealed the presence of carbapenem-resistant A. baumannii within a mixed 
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bacterial culture. The A. baumannii isolate belonged to ST294 and contained a plasmid-
mediated blaOXA-72 gene [105]. Three A. baumannii ST20, ST492, ST493 containing blaOXA-23 
were recovered from the feces of fowls in Lebanon; A. baumannii ST20 also contained the 
blaOXA-58  gene [77]. 
  
7. A. baumannii susceptibility 
 
According to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
expert rules regarding human isolates, A. baumannii is naturally (or intrinsically) resistant to 
the following antimicrobials: ampicillin, amoxycillin-clavulanate, cefazolin, cefotaxime, 
ceftriaxone, ertapenem, trimethoprim and fosfomycin [106]. Therefore, the list of 
antimicrobials that are usually active against wildtype A. baumannii infections is already short 
consisting of carbapenems (doripenem, imipenem and meropenem), polymyxins [colistin 
(polymyxin E) and polymyxin B], tigecycline, FQs, and aminoglycosides [107]. However, most 
of the above available treatment options can also be shrunk by further mechanisms of resistance 
due to the acquisition of mobile genetic elements (e.g., plasmids, IS elements, transposons) 
and/or chromosomal mutations (e.g., those in the gyrA and parC genes and affecting 
FQs)(Table 2). It should be realized that available treatment options are mainly derived from 
human studies. 
In a recent study [108], the best approach to treat MDR A. baumannii pneumonia in critically 
ill patients has been assessed based on estimates of Bayesian network meta-analysis reported 
as rank probabilities to identify the relative rankings of antimicrobial treatments based on the 
surface under the cumulative ranking curve, ranging from 0% (statistically certain to be the 
worst treatment) to 100% (statistically certain to be the best treatment). The best approach to 
treat MDR A. baumannii pneumonia in critically ill patients with antimicrobials showed to be 
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in the following order fosfomycin + IV colistin, inhaled colistin + IV colistin, high dose 
tigecycline (defined as a total daily dose of 200 mg/day after a loading dose of 200 mg), and IV 
colistin therapy. However, resistance to these antimicrobials has also been reported and the 
advent of pan-drug resistance might become a very plausible and concerning scenario 
[1,10,24,109-111]. Carbapenem-resistant A. baumannii (especially those producing the OXA-
23 carbapenemase) has become common in many hospitals. Moreover, such isolates are 
frequently co-resistant to all other antimicrobial families (e.g., aminoglycosides and FQs) 
routinely tested. Therefore, the treatment of carbapenem- and/or pandrug-resistant A. 
baumannii infection involves the use of combinations of last resort agents such as colistin and 
sometimes tigecycline, but the efficacy and safety of these approaches are yet well determined 
[10,112]. Of interest, a systematic review and meta-analysis favoured the clinical use of 
antimicrobial monotherapy in contrast to a tigecycline-based combination therapy regimen for 
the treatment of MDR A. baumannii infections [113]. However, the value of tigecycline 
combination therapy managing pandrug- or extensively drug-resistant A. baumannii ventilator-
associated pneumonia needs further evaluation [114]. 
In veterinary medicine, there is no such standard approach and treatment of diseased animals 
suffering from MDR A. baumannii strains is mostly supportive and specific therapies should be 
preferably based on in vitro antimicrobial susceptibility testing (AST). The emergence of 
carbapenem-resistance in clinical A. baumannii isolates from animals should stress usage of 
AST. These isolates exhibit frequently a MDR profile associated with the acquisition of 
additional resistance genes conferring resistance to aminoglycosides, tetracyclines, and 
sulfonamides (Table 2), leaving colistin one of the last active antimicrobial.   
In veterinary farm animal medicine, colistin has been used for decades for the treatment and 
prevention of infectious diseases. Colistin has been administered frequently as a group 
treatment for animal gastrointestinal infections caused by Gram-negative bacteria within 
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intensive husbandry systems. Despite its extensive use in veterinary medicine, there had been 
limited evidence for the development of resistance to the drug and for the transmission of 
resistance to colistin in bacteria that have spread from animals to humans [115]. However, 
resistance to colistin may occur by point mutations in A. baumannii [116], and a recent report 
showed the presence of a plasmid-mediated colistin resistance gene mcr-1 in 
Enterobacteriaceae [117]. It is likely a question of time to also see mcr-1 in Acinetobacter spp. 
As antimicrobial therapeutical options are also limited in veterinary medicine, to our opinion 
regarding treatment of diseased animals suffering from MDR A. baumannii consulting in vitro 
AST should be mandatory as standard approach before the use of last resort antimicrobials.  
8. Vaccination 
 
The first steps towards a vaccine against A. baumannii include the identification of antigen 
candidates [118]. A limitation of this approach, however, is that the strain-to-strain variation in 
carbohydrate structures is so great that a multivalent vaccine to target all pathogenic 
Acinetobacter is unrealistic [119,120]. 
 
 
 
9.  Prevention 
As mentioned before, members of the genus Acinetobacter are considered ubiquitous organisms 
[16] as Acinetobacter species prevail in natural environments, including soils, fresh water, 
oceans, trout intestinal contents, frozen shrimps, meat, sediments, the polar region, and 
hydrocarbon-contaminated sites [1,42,119,121-122]. In addition, species of the genus 
Acinetobacter normally reside on the human skin, oropharynx, and perineum [123] and were 
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recovered from human milk [125-126]. Early detection combined with ASTs and 
implementation of rigorous infection control measures is essential to prevent major outbreaks 
due to MDR A. baumannii that has a high potential to spread among patients [10,126] and staff 
[84]. The most likely explanation for the isolation of the same strain from consecutive patients 
in the same ward is patient-to-patient transmission of the isolate, usually through the hands of 
staff, contaminated equipment, or the overall hospital environment [1,2,127]. It should be 
realized that available preventive measures are mainly derived from human studies. 
Given the rapid spread of MDR A. baumannii in clinical institutions, two different approaches 
are essential to limit the spread of antimicrobial-resistant A. baumannii, namely infection 
control and antimicrobial control programs. The first approach requires compliance with a 
series of methods including strict environmental cleaning, effective sterilization of reusable 
medical equipment, concentration on proper hand hygiene practices, and use of contact 
precautions, together with appropriate administrative guidance. The second strategy is also of 
paramount importance. Both are essential for control of antimicrobial-resistant A. baumannii 
spread and infections [16,125,128]. In line, it is critical for the veterinary community to engage 
in discussions pertaining to prudent and effective use of antimicrobials and to consider ways to 
improve antimicrobials use practices, to optimize animal care, reduce antimicrobial resistance 
selection pressure and maintain access to important antimicrobial agents. However, there are 
no simple solutions to this complex problem, yet veterinarians must consider the influence of 
the decisions that they make on a daily basis and optimize antimicrobial use for the benefit of 
their patients and society as a whole [129]. 
Furthermore, innovations associated with potent antibacterial efficacy against MDR isolates of 
A. baumannii should be mentioned here too. For instance light modulates the ability of A. 
baumannii to persist in the environment, its virulence against eukaryotic hosts, and even 
susceptibility to certain antimicrobials. The light signal is sensed through different mechanisms, 
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in some cases involving specialized photoreceptors of the BLUF-type, whereas in others 
directly by a photosensitizer molecule [130]. Continuous flow-through unit (45 J/cm2) UVC 
treatment of sterile, colostrum and commercial whole milk inoculated with A. baumannii caused 
a significant reduction of bacterial counts [131]. In addition, both maleic anhydride-based novel 
cationic polymers appended with amide side chains [49] and an electrochemical scaffold that 
generates a local low concentration of hydrogen peroxide [130] showed to disrupt surface 
established MDR A. baumannii biofilms. As a consequence, these innovations were associated 
with potent antibacterial efficacy against MDR A. baumannii with minimal toxicity to 
mammalian cells. Furthermore, newly isolated bacteriophages can serve as potential candidates 
for phage cocktails to control A. baumannii infections [132]. Nevertheless, antimicrobials 
remain to date the therapeutic option and it is therefore of major importance to use them 
appropriately after consulation of an antibiogramm and in case of infections only. 
There is an increase of awareness regarding antimicrobial stewardship in veterinary medicine 
[133]. Establishment of antimicrobial stewardship programs requires (1) coordination ideally 
by an infectious diseases specialist or at least by a clinician with strong interest in and good 
knowledge of antimicrobial resistance and therapy, (2) commitment by the clinical staff, and 
(3) collaboration with the microbiology laboratory. 
Although the problems associated with healthcare-associated infections and the emergence of 
zoonotic and MDR pathogens in companion animal (dogs, cats and horses) medicine have been 
well-known for decades, current progress with respect to practical implementation of infection 
control programs in veterinary clinics has been limited [134]. Significantly reducing 
transmission of infections in small animal veterinary clinics, as in human hospitals, will require 
“clear goals, a committed leadership, access to resources, a best-practice mindset, effective 
people management, and ongoing vigilance” [135]. However, this field needs more awareness 
in veterinary medicine. For instance, about half the small animal practitioners and less than a 
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third of the large animal or equine practitioners reported always washing their hands before 
eating, drinking or smoking. The frequency of hand washing between contacts with patients 
was even lower [136,137]. Increasing concerns about zoonoses and antimicrobial resistance are 
bringing public health and private veterinary practice together. An emphasis on prevention will 
pay rich dividends for the safety of our patients and staff and the broader community [137]. 
 
10.  Public Health Significance 
 
Most A. baumannii infections in humans involve the respiratory tract, but bacteremia, 
meningitis, UTI, (prosthetic) valve endocarditis, endophthalmitis, keratitis and wound/soft 
tissue infection may also occur [10,16,124], especially in ICUs [1,138]. Community-acquired 
A. baumannii is a rare, but serious cause of community-acquired pneumonia in tropical regions 
of the world. These infections predominantly affect individuals with risk factors, which include 
excess alcohol consumption, diabetes mellitus, smoking, and chronic lung disease. Community-
acquired A. baumannii pneumonia presents a surprisingly fulminant course and is characterized 
by a rapid onset of fever, severe respiratory symptoms, necrotising fasciitis and multi-organ 
dysfunction, with a mortality rate reported as high as 64% [16,139-143].  
The rapid spread of MDR A. baumannii in clinical institutions has made choosing an adequate 
antimicrobial to treat these infections and executing contact precaution to isolate these MDR A. 
baumannii difficult for clinicians [125,128].  
Since animals may represent a reservoir for A. baumannii, it is of public health importance to 
avoid selecting MDR strains through the uncontrolled application of clinically essential 
antimicrobials.  
Conclusions 
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A. baumannii represents nowadays an important veterinary nosocomial pathogen. However, it 
seems that the majority of A. baumannii infections in veterinary medicine are secondary and as 
a sequela might be fatal or lead to euthanasia in some cases. The recent report on A. baumannii 
infection in farmed mink might be regarded as an exception with reference to the associated 
fatal pneumonia. In other species relevant to veterinary medicine fatal pneumonia as a sequela 
of A. baumannii infection seems rare. Emergence of cases of infections in companion animals 
associated with carbapenem-resistant isolates emphasizes the need for accurate diagnostics. 
Treatment of diseased animals is often supportive and specific treatment should be based 
preferably on in vitro ASTs. Although the role of animals is still not clear in the dissemination 
of specific clones into the human community and hospitals, studies have demonstrated that 
similar or even identical A. baumannii clones have been identified in both settings. However, 
this finding is limited to hospitalized animals with nosocomial infections. It is therefore of 
major importance to avoid the selection and spread of MDR A. baumannii in animals as it is in 
humans, use targeted antimicrobial therapy as well as implement infection control. Among 
effective control procedures of antimicrobial-resistant A. baumannii infections in veterinary 
hospitals in our experience concentration on proper hand hygiene practices is the key. 
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Table 1. Overview of methodologies used for the identification of Acinetobacter isolated from 
animals.  
Anim
al  
Infection 
site 
Identifica
tion 
method 
Referen
ce 
method
ology 
Species 
identification 
at time of 
publication 
Reliable 
identific
ation 
Year 
of 
public
ation 
Refer
ence 
Dog 
(n=2) 
UTI NM rpoB 
sequenci
ng 
A. baumannii yes 2016 5 
Dog 
(n=16
8) 
Urine, 
central 
venous 
catheters, 
throat and 
trachea, 
skin and 
hairs, 
bronchoal
veolar 
lavages, 
nose, 
abcesses 
and fistula  
MALDI-
TOF MS 
(Bruker) 
gyrB 
multiple
x PCR 
A. baumannii yes 2017 89 
Dog 
(n=4) 
Mouth 
and rectal 
swabs 
VITEK 
® 
2 system 
(bioMérie
ux) 
PCR of 
rpoB  
A. baumannii yes 2016 91 
Dog 
(n=11
) 
Pus/woun
d, eye, 
urine, 
blood and 
pericardia
l effusion  
MALDI-
TOF MS 
(Bruker) 
PCR of 
blaOXA-
51-like 
A. baumannii yes 2011 3 
Dog 
(n=17
) 
Pus/woun
d, urinary 
tract, 
respirator
y tract 
and blood  
API 
ID32GN 
galleries 
(bioMérie
ux) 
Sequenc
ing of 
16S 
ribosom
al DNA 
of 
selected 
isolates 
A. baumannii yes 2000 83 
Dog 
(n=5) 
Samples 
routinely 
submitted 
for 
in-house 
aerobic 
bacteriolo
gic 
culture  
none A. baumannii no 2009 85 
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bacteriolo
gic 
culture 
and 
susceptibi
lity 
testing  
Dog 
(n=5) 
Gingival 
scrapings 
from 
healthy 
dogs 
non 
specified 
standard 
biochemi
cal 
procedure
s  
none A. 
calcoaceticus 
var. lwoffi 
(n=4) and 
anitratus (n=1) 
no 1976 86 
Dog 
(n=1) 
Ulcerated 
pyoderma 
lesions 
non 
specified 
API 
galleries  
none A. 
baumannii/calc
oaceticus 
no 2014 87 
Dog 
(n=10
) 
Chronic 
eczema 
Gram-
negative, 
penicillin-
resistant, 
oxidase 
negative 
coccobaci
lli 
none Acinetobacter 
sp. 
no 1978 88 
Dog 
(n=1) 
UTI MALDI-
TOF MS 
(Bruker) 
Whole 
genome 
sequenci
ng 
A. baumannii yes 2018 81 
Cat 
(n=5) 
UTI NM rpoB 
sequenci
ng 
A. baumannii yes 2016 5 
Cat 
(n=42
) 
Wounds, 
urine, 
throat and 
trachea, 
skin and 
hairs, 
nose, 
abcesses 
and fistula  
MALDI-
TOF MS 
(Bruker) 
gyrB 
multiple
x PCR 
A. baumannii yes 2017 89 
Cat 
(n=1) 
Urine NM Whole 
genome 
sequenci
ng 
A. baumannii yes 2016 90 
Cat 
(n=2) 
Pus/woun
d and 
liver  
MALDI-
TOF MS 
(Bruker) 
PCR of 
blaOXA-
51 
A. baumannii yes 2011 3 
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Cat 
(n=2) 
NM API 
ID32GN 
galleries 
(bioMérie
ux) 
Sequenc
ing of 
16S 
ribosom
al DNA 
 
A. baumannii yes 2000 83 
Cat 
(n=?) 
Chronic 
eczema 
Gram-
negative, 
penicillin-
resistant, 
oxidase 
negative 
coccobaci
lli 
none Acinetobacter 
sp. 
no 1978 88 
Cat 
(n=1) 
Skin, 
liver, 
spleen 
and 
kidney 
API 
ID32GN 
galleries 
(bioMérie
ux) 
PCR of 
blaOXA-
51-like 
gene  
A. baumannii yes 2007 92 
Cat 
(n=1) 
UTI MALDI-
TOF MS 
(Bruker) 
PCR of 
blaOXA-
51-like 
gene 
A. baumannii yes 2014 80 
Horse 
(n=9) 
Feacal 
samples, 
nostrail 
swabs 
MALDI-
TOF MS 
(Bruker) 
none A. baumannii yes 2018 146 
Horse 
(n=4) 
Pus/woun
d  and 
catheter-
tip  
MALDI-
TOF MS 
(Bruker) 
PCR of 
blaOXA-
51-like 
gene  
A. baumannii yes 2011 3 
Horse 
(n=2) 
faeces of 
hospitaliz
ed horses 
selective 
Acinetoba
cter 
medium 
Sequenc
ing of 
16S 
ribosom
al DNA  
Possibly novel 
Acinetobacter 
species 
 
yes 2012 93 
Horse 
(n=7) 
intraveno
us jugular 
catheter 
tips 
API 
20NE 
galleries 
and 
growth at 
44°C as 
complem
entary 
test g 
amplifie
d 
ribosom
al DNA 
restricti
on 
analysis 
(ARDR
A) 
A. baumannii yes 2000 94 
Horse 
(n=24
) 
tracheal 
washes 
from 
horses 
with 
bacteriolo
gical 
culture 
and 
subseque
NM  no 1993 96 
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respirator
y diseases  
or 'poor 
performan
ce'  
nt 
biochemi
cal 
characteri
zation 
revealing 
Acinetoba
cter spp. 
Foal 
(n=1) 
blood blood 
culture 
with 
undefined 
identificat
ion 
method 
none A. baumannii no 2002 98 
Foal 
(n=1) 
a 
percutane
ous 
transtrach
eal wash 
bacteriolo
gical 
culture 
none A. baumannii no 2010 145 
Cow 
(n=1) 
faeces API 20E 
galleries, 
(Biomérie
ux), 
Sensititre 
GNID 
(TREK 
Diagnosti
c Systems 
Inc.) 
Whole 
genome 
sequenci
ng 
A. baumannii yes 2016 99 
Cow 
(n=1) 
faeces MALDI-
TOF MS  
none A. baumannii yes 2015 77 
Cow 
(n=8) 
recovered 
from 
faecal 
specimens
, skin, 
nostril 
and ear 
swabs  
NM amplifie
d 
ribosom
al DNA 
restricti
on 
analysis 
(ARDR
A) and 
PCR of 
blaOXA-
51-like 
gene  
A. baumannii yes 2011 76 
Cattle 
(n=5) 
Mouth 
swabs 
VITEK® 
2 system 
(bioMérie
ux) 
PCR of 
rpoB  
A. baumannii yes 2016 142 
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Cattle 
(n=8) 
Faecal 
and 
nostril 
samples 
API 20E 
galleries, 
(Biomérie
ux), 
amplifie
d 
ribosom
al DNA 
restricti
on 
analysis 
(ARDR
A) 
A. baumannii yes 2008 22 
Pig 
(n=1) 
faeces MALDI-
TOF MS 
none A. baumannii yes 2015 77 
Pig 
(n=8) 
recovered 
from 
faecal 
specimens
, skin, 
nostril 
and ear 
swabs  
NM amplifie
d 
ribosom
al DNA 
restricti
on 
analysis 
(ARDR
A) and 
PCR of 
blaOXA-
51-like 
gene  
A. baumannii yes 2011 76 
Pig 
(=1) 
lung NM NM A. baumannii no 2013 78 
Pig 
(n=8) 
Faecal 
samples 
API 20E 
galleries, 
(Biomérie
ux), 
amplifie
d 
ribosom
al DNA 
restricti
on 
analysis 
(ARDR
A) 
A. baumannii yes 2008 22 
Meat  Chicken 
(n=43), 
turkey 
(n=4), 
Veal 
(n=9), 
pork 
(n=3) and 
beef 
(n=3) 
MALDI-
TOF MS 
(Bruker) 
none A. baumannii yes 2014 42 
Ameri
can 
Mink 
(Neov
ison 
liver and 
lung 
MALDI-
TOF MS 
(Bruker) 
Sequenc
ing of 
16S 
ribosom
al DNA 
A. baumannii yes 2015 102 
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vison) 
cadav
ers 
(n=3) 
Europ
ean 
Mink 
(Must
ela 
lutreol
a) 
(n=1) 
lung and 
kidney 
API20NE 
galleries 
and 
MALDI-
TOF MS 
none A. baumannii yes 2017 103 
Falco
n 
(n=12
) 
cutaneous 
lesions 
Sequenci
ng of 16S 
ribosomal 
DNA 
amplified 
by PCR 
directly 
from 
DNA 
extracted 
from 
fresh 
tissue 
Sequenc
e 
analysis 
of the 
16S-23S 
rRNA 
gene 
spacer 
region 
A. baumannii yes 2010 104 
Fowl 
(n= 3) 
faeces MALDI-
TOF MS 
none A. baumannii yes 2015 77 
Parrot 
(n=1) 
choanal 
swab 
MALDI-
TOF MS 
(Bruker) 
Whole 
genome 
sequenci
ng 
A. baumannii yes 2018 144 
Others 
(n=13
) 
includ
ing 
rabbit, 
ferret, 
snake, 
rat 
and 
duck 
NM 
specificall
y 
MALDI-
TOF MS 
(Bruker) 
gyrB 
multiple
x PCR 
A. baumannii yes 2017 89 
NM = not mentioned 
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Table 2. Transmissible antibiotic resistance genes identified in carbapenemase-containing 
Acinetobacter species from animals 
 
Antibiotic classes and 
resistance genes 
Acinetobacter species Animal hosts Country 
Genetic location 
(plasmid/transposon) 
Reference 
Carbapenems      
blaOXA-23 A. baumannii dog Germany Plasmid:Tn2008 89 
blaOXA-23 A. baumannii cat Germany pOXA-23-IHIT7853 90 
blaOXA-23 A. baumannii dog France ND 91 
blaOXA-23 A. baumannii cat, dog France Chromosome:Tn2008B 5 
blaOXA-23 A. baumannii cat Portugal Tn2006 80 
blaOXA-23 A. baumannii dog Thailand Tn2006 81 
blaOXA-23 A. baumannii cattle, pig, 
fowl 
Lebanon ND 77 
blaOXA-23 A. variabilis (15TU) cattle France Unknown:Tn2008 100 
blaOXA-23 A. indicus-like cattle Germany Chromosome:ΔTn2008 101 
blaOXA-23 A. radioresistens cat, dog Japan ND 143 
blaOXA-23 Acinetobacter sp. horse Belgium ND 93 
blaOXA-24 A. baumannii cattle France 
(Reunion 
Island) 
ND 142 
blaOXA-58 A. pittii dog, cat Germany pAP24944-OXA58 143 
 A. baumannii fowl Lebanon ND 77 
blaOXA-72 A. baumannii parrot Luxemburg pIHIT32296 144 
blaNDM-1 A. baumannii pig China pNDM-AB 78 
 A. lwoffii chicken China pAL-01 147 
 A. lwoffii cat China pNDM-Iz4b 78 
blaIMP-1 A. radioresistens cat, dog Japan ND 143 
Aminoglycosides 
     
aph(3′)-VI (aph6) A. baumannii pig China pNDM-AB 78 
 A. baumannii cat Germany ND 90 
 A. radioresistens cat Japan ND 143 
aph(3′)-Ic A. pittii dog, cat Germany ND 89 
 A. indicus-like cattle Germany ND 101 
aac(3)-Ia (aac1) A. baumannii dog Germany ND 89 
 A. baumannii cat Germany ND 90 
 A. baumannii dog Thailand ND 81 
aac(3)-IIc (aacC2) A. pittii dog, cat Germany ND 89 
aac(3)-IIa A. indicus-like cattle Germany ND 101 
aac(6')-31 A. radioresistens cat, dog Japan ND 143 
aac(6')-Im A. baumannii dog Thailand ND 81 
aadA1 A. baumannii cat Germany ND 90 
aadB A. indicus-like cattle Germany ND 101 
 A. radioresistens cat, dog Japan ND 143 
strA strB A. baumannii cat Germany pOXA-23-IHIT7853 90 
 A. baumannii cat Portugal ND 80 
 A. baumannii dog Thailand ND 81 
 A. pittii dog, cat Germany pAP24944-OXA58 89 
 A. radioresistens cat Japan ND 143 
 A. indicus-like cattle Germany ND 101 
Tetracyclines 
     
tet(A) A. baumannii cat Germany ND 90 
 A. indicus-like cattle Germany ND 101 
tet(B) A. baumannii cat Portugal ND 80 
 A. baumannii dog Thailand ND 81 
tet(X) A. indicus-like cattle Germany ND 101 
tet(Y) A. indicus-like cattle Germany ND 101 
tet(39) A. pittii dog, cat Germany pAP24944-OXA58 89 
Sulfonamides 
     
sul1 A. baumannii cat Germany ND 90 
 A. radioresistens cat, dog Japan ND 143 
 A. indicus-like cattle Germany ND 101 
sul2 A. pittii dog, cat Germany pAP24944-OXA58 89 
 A. radioresistens cat Japan ND 143 
 A. indicus-like cattle Germany ND 101 
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Macrolides 
     
msr(E)-mph(E) A. baumannii pig China pNDM-AB 78 
Phenicols 
     
floR A. indicus-like cattle Germany ND 101 
catA1 A. baumannii cat Germany ND 90 
ND, not determined 
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